| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8526288 | Biomedicine & Pharmacotherapy | 2018 | 9 Pages |
Abstract
In summary, these results provide a preclinical rationale to combine a HDACi with a PARP inhibitor to reduce HR efficiency in TNBC and sensitize these aggressive tumors to PARP inhibition.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Hélène Marijon, Dhong Hyun Lee, LingWen Ding, Haibo Sun, Sigal Gery, Aimery de Gramont, H. Phillip Koeffler,